Katherine Talcott

1 week ago | ophthalmologytimes.com | Martin Harp |Katherine Talcott |Hattie Hayes

At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study. The research she presented focused on neovascular age-related macular degeneration (AMD). "This is actually the first phase 2 study looking at a tyrosine kinase inhibitor for wet AMD," Dr. Talcott told the Eye Care Network.